Table 1.
Demographics and clinical characteristics of the study population.
| FES | Schizophrenia | Control | p Value | ||
|---|---|---|---|---|---|
| Number of patients | 51 | 49 | 50 | - | |
| Male gender (n, %) | 28, 54.9% | 24, 48.98% | 34, 68% | 0.55 | |
| Mean age (±SD) | 26.35 ± 3.81 | 40.08 ± 2.89 | 34.60 ± 8.01 | <0.0001 | |
| Onset age (±SD) | 25.12 ± 3.75 | 24.96 ± 2.99 | NA | 0.81 | |
| Duration of illness (±SD) | 1.20 ± 0.63 | 15.12 ± 4.04 | NA | <0.0001 | |
| Antipsychotic treatment | |||||
| FES | Mean dose (mg) | Chlorpromazine equivalent (mg) | SCZ | Mean dose (mg) | |
| Amisulpride (n, %) | 3, 5.88% | 533.33 | 533.33 | 4, 8.16% | 650 |
| Aripiprazole (n, %) | 6, 11.77% | 25 | 333.33 | 3, 6.12% | 20 |
| Clozapine (n, %) | 0 | - | - | 8, 16.33% | 312.5 |
| Olanzapine (n, %) | 16, 31.37% | 19.06 | 381.25 | 21, 42.86% | 16.75 |
| Quetiapine (n, %) | 7, 13.73% | 414.29 | 555.55 | 3, 6.12% | 666.67 |
| Paliperidone (n, %) | 5, 9.80% | 7.2 | 360 | 3, 6.12% | 9 |
| Risperidone (n, %) | 14, 27.45% | 3.93 | 196.43 | 7, 14.29% | 5.14 |